Pereira de Carvalho Florido M, Ferreira de Paula P, Isaac L
Clin Diagn Lab Immunol. 2003; 10(2):216-20.
PMID: 12626445
PMC: 150543.
DOI: 10.1128/cdli.10.2.216-220.2003.
Meri S
Clin Exp Immunol. 2001; 124(3):369-76.
PMID: 11472396
PMC: 1906070.
DOI: 10.1046/j.1365-2249.2001.01523.x.
van Kessel K, Antonissen A, Van Dijk H, Rademaker P, Willers J
Infect Immun. 1981; 34(1):16-9.
PMID: 6795123
PMC: 350813.
DOI: 10.1128/iai.34.1.16-19.1981.
MULLER-EBERHARD H
Springer Semin Immunopathol. 1984; 7(2-3):93-141.
PMID: 6387983
DOI: 10.1007/BF01893017.
Ohanian S
Surv Immunol Res. 1983; 2(2):122-8.
PMID: 6316456
DOI: 10.1007/BF02918569.
Relationships among the complement, kinin, coagulation, and fibrinolytic systems.
Sundsmo J, Fair D
Springer Semin Immunopathol. 1983; 6(2-3):231-58.
PMID: 6227099
DOI: 10.1007/BF00205875.
Complement-mediated lysis of liposomes produced by the reactive lysis procedure.
LACHMANN P, Munn E, Weissmanng
Immunology. 1970; 19(6):983-6.
PMID: 5530596
PMC: 1455672.
Complement metabolism in the seronegative arthritides.
Whaley K, Canesi B, Moseley A, Morrow W, Sturrock R, Mitchell W
Ann Rheum Dis. 1974; 33(6):495-9.
PMID: 4441129
PMC: 1006314.
DOI: 10.1136/ard.33.6.495.
Bypass-activation of the complement system starting with C3. I. Generation and function of an enzyme from a factor of guinea-pig serum and cobra venom.
Bitter-Suermann D, Dierich M, Konig W, HADDING U
Immunology. 1972; 23(3):267-81.
PMID: 4214761
PMC: 1407940.
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.
LACHMANN P, Thompson R
J Exp Med. 1970; 131(4):643-57.
PMID: 4193935
PMC: 2138770.
DOI: 10.1084/jem.131.4.643.
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7.
Thompson R, LACHMANN P
J Exp Med. 1970; 131(4):629-41.
PMID: 4193934
PMC: 2138783.
DOI: 10.1084/jem.131.4.629.
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay.
McLeod B, Baker P, Gewurz H
Immunology. 1974; 26(6):1145-57.
PMID: 4137213
PMC: 1423360.
Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinase.
Reed S, Gigli I
J Clin Invest. 1990; 86(6):1815-22.
PMID: 2254446
PMC: 329813.
DOI: 10.1172/JCI114911.
Studies of the action of some anti-inflammatory drugs on complement mediated immune haemolysis.
Whaley K, Sloane D
Br J Clin Pharmacol. 1975; 2(2):123-9.
PMID: 1234496
PMC: 1402515.
DOI: 10.1111/j.1365-2125.1975.tb01567.x.
Binding of the complement intermediate C56 to zymosan in acute phase human sera.
Baker P, Rubin L, Lint T, McLeod B, Gewurz H
Clin Exp Immunol. 1975; 20(1):113-24.
PMID: 1106918
PMC: 1538180.
The enhancement of the haemolytic activity of the first component of complement by trasylol.
Delage J, Simard J
Immunology. 1976; 31(4):601-6.
PMID: 1086286
PMC: 1445372.
Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
Tamura N, Baba A
Immunology. 1976; 31(1):151-8.
PMID: 1027719
PMC: 1445084.
The complement profile in relation to the "reactor" state: a study in the immediate post-partum period.
Mak L
Clin Exp Immunol. 1978; 31(3):419-25.
PMID: 657587
PMC: 1541242.
Inherited deficiency of the seventh component of complement associated with nephritis. Propensity to formation of C56 and related C7-consuming activity.
Nemerow G, Gewurz H, Osofsky S, Lint T
J Clin Invest. 1978; 61(6):1602-10.
PMID: 350902
PMC: 372686.
DOI: 10.1172/JCI109080.
Haemolytic complement in peripheral lymph of normal men.
Olszewski W, Engeset A
Clin Exp Immunol. 1978; 32(3):392-8.
PMID: 99278
PMC: 1541330.
